Objective:Endometriosis is inherited as a complex trait, which means that multiple susceptibility genes interact with each other and the environment to produce the phenotype. Previous studies have implicated p53, a tumor suppressor gene, as a factor in the development of the disease. In a Japanese population, we investigated the frequency of the p53 polymorphism in women affected with endometriosis.
Methods:We compared the distribution of the p53 codon 72 polymorphism in endometriosis cases (n = 111) and population controls consisting of female neonates (n = 180) by using polymerase chain reaction restriction fragment-length polymorphism analysis in a Japanese population.
Results:The frequencies of the three p53 genotypes, Arginin (Arg)/Arg, Arg/Proline (Pro), and Pro/Pro in controls were 39.4%, 41.7%, and 18.9%, respectively. The crude genotype frequencies in the endometriosis cases were similar to those of the controls (35.2%, 48.5%, and 16.2%, respectively). Using the Arg/Arg genotype as the reference, the odds ratios of the Arg/Pro and Pro/Pro genotypes were 1.30 (95% confidence interval [CI] 0.72-1.86, P = .33) and 0.96 (95% CI 0.47-1.94, P = .91), respectively. Thus, there were no significant differences in the frequency of the p53 codon 72 polymorphism between endometriosis cases and controls in this population. The endometriosis cases with severe disease only were also evaluated, but no significant difference was observed in the frequency of the polymorphism betweeen this subgroup and the conotrols.
Conclusion:Our findings suggest that the p53 codon 72 polymorphism is unlikely to be associated with endometriosis in Japanese women.
3. Treloar SA, Hadfield R, Montgomery G, et al. The International Endogene Study: A collection of families for genetic research in endometriosis. Fertil Steril2002;78:679-685.
6. Kennedy SH, Hadfield RM, Westbrook C, Weeks DE, Barlow DH, Golding S. Magnetic resonance imaging to assess familial risk in relatives of women with endometriosis. Lancet1998;352:1440-1441.
7.
7. Simpson JL, Elias S, Malinak LR, Buttram VCJ. Heritable aspects of endometriosis. I. Genetic studies. Am J Obstet Gynecol1980;137:327-331.
8.
8. Coxhead D, Thomas EJ. Familial inheritance of endometriosis in a British population. A case control study. J Obstet Gynaecol1993;13:42-44.
9.
9. Moen MH, Magnus P. The familial risk of endometriosis. Acta Obstet Gynecol Scand1993;72:560-564.
10.
10. Zondervan KT, Cardon LR, Kennedy SH. The genetic basis of endometriosis. Curr Opin Obstet Gynecol2001;13:309-314.
11.
11. Swiersz LM. Role of endometriosis in cancer and tumor development. Ann N Y Acad Sci2002;955:281-292. discussion 293-5, 396-406.
12.
12. Jiang X, Hitchcock A, Bryan EJ, et al. Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res1996;56:3534-3539.
13.
13. Jimbo H, Hitomi Y, Yoshikawa H, et al. Evidence for monoclonal expansion of epithelial cells in ovarian endometrial cysts. Am J Pathol1997;150:1173-1178.
14.
14. Tamura M, Fukaya T, Murakami T, Uehara S, Yajima A. Analysis of clonality in human endometriotic cysts based on evaluation of X chromosome inactivation in archival formalin fixed, paraffin-embedded tissue. Lab Invest1998;78:213-218.
15.
15. Bischoff FZ, Heard M, Simpson JL. Somatic DNA alterations in endometriosis: High frequency of chromosome 17 and p53 loss in late-stage endometriosis. J Reprod Immunol2002;55:1-2.
16.
16. Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ. P53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet1998;352:871-872.
17.
17. Kupryjanczyk J, Bell DA, Yandell DW, Scully RE, Thor AD. P53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol1994;102:671-676.
18.
18. Takeda A, Shimada H, Nakajima K, Suzuki T, Hori S, Hayashi H. Impact of circulating p53 autoantibody monitoring after endoscopic resection in mucosal gastric cancer. Endoscopy2000;32:740-741.
19.
19. Wang YC, Lee HS, Chen SK, Chang YY, Chen CY. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer1999;35:226-230.
20.
20. Pich A, Margaria E, Chiusa L. Oncogenes and male breast carcinoma: c-erB-2 and p53 coexpression predicts a poor survival. J Clin Oncol2000;18:2948-2956.
21.
21. Chang CC, Hsieh YY, Tsai FJ, Tsai CH, Tasi HD, Lin CC. The proline form of p53 codon 72 polymorphism is associated with endometriosis. Fertil Steril2002;77:43-45.
22.
22. American Fertility Society. Revised American Fertility Society classification of endometriosis. Fertil Steril1985;43:351-352.
23.
23. Ara s, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res1990;18:4961-4961.
24.
24. Witz CA, Burns WN. Endometriosis and infertility: Is there a case and effect relationship?Gynecol Obstet Invest2002;53(Suppl 1):2-11.
25.
25. Moen MH. Endometriosis in women at interval sterilization. Acta Obstet Gynecol Scand1987;66:451-454.
26.
26. Ekwempu CC, Harrison KA. Endometriosis among the Hausa/Fulani population of Nigeria. Trop Geogr Med1979;31:201-205.
27.
27. Barbieri RL. Etiology and epidemiology of endometriosis. Am J Obstet Gynecol1999;162:565-567.
28.
28. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis1996;17:261-264.
29.
29. Wu WJ, Kakehi Y, Habuchi T, et al. Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn J Cancer Res1995;86:730-736.
30.
30. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis1993;14:1085-1089.
31.
31. Zondervan KT, Cardon LR, Kennedy SH. Waht makes a good case-control study? Design issues for complex traits such as endometriosis. Hum Reprod2002;17:1415-1423.
32.
32. Beckman G, Birgander R, Sjalander A, et al. Is p53 polymorphism maintained by natural selection?Hum Hered1994;44:266-270.
33.
33. Shepherd T, Tolbert D, Bnenedetti J, et al. Alterations in exon 4 of the p53 gene in gastric carcnoma. Gastroenterology2000;118:1039-1044.
34.
34. Malcolm EK, Baber GB, Boyd JC, Stoler MH. Polymorphism at codon 72 of p53 is not associated with cervical cancer risk. Mod Pathol2000;13:373-378.
35.
35. Hollstein M, Sidransky D, Vogelstein B, Harris C. P53 mutations in human cancers. Science1991;253:49-53.
36.
36. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature1998;393:229-234.
37.
37. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol1999;19:1092-1100.
38.
38. Wu X, Zhao H, Amos CI, et al. P53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst2002;94:681-690.
39.
39. Terakawa N. Epidemiology of endometriosis. Nippon Rinsho2001;59(Suppl 1):8-12.
40.
40. Weston A, Ling-Cawley HM, Capaoraso NE, et al. Determination of the allele frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis1994;14:583-587.
41.
41. Fan R, Wu MT, Miller D, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev2000;9:1037-1042.
42.
42. Lee JM, Lee YC, Yang SY, et al. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer2000;89:458-464.
43.
43. Kawaguchi H, Ohno S, Araki K, et al. P53 polymorphism in human papilloma virus associated esophageal cancer. Cancer Res2000;60:2753-2755.
